Abstract 321P
Background
Ovarian cancer(OC) is the third most common gynaecological cancer in Indian according to Globocan 2020. The majority of patients are diagnosed in advanced stage III and IV. The aim of this study was to evaluate clinical epidemiology and survival outcomes in patients with epithelial ovarian cancer.
Methods
This was a retrospective analysis of patients with epithelial OC who were treated at Asian Institute of Medical Sciences from 1st January 2016 to 31st December 2020. Patient’s sociodemographic characteristics, clinicopathological details like the stage of cancer, treatment received and follow up details was extracted from medical records. All statistical analysis was performed using Microsoft Excel 2016 and R software (Rx 64 version 3.6.2). Survival was estimated by the Kaplan Meier method and compared by the log-rank test.
Results
251 OC patients records were evaluated, epithelial OC constituted 94%(n=235), with a median age 49 years. Majority 81%(n=190) of the patients were in stage III or IV at the time of diagnosis. The main presenting symptoms were abdominal distension 65%(n=153) and gastrointestinal disturbances including pain abdomen 45%(n=106). The most common histologic types were serous 76%(n=179) followed by mucinous carcinoma 18%(n=42). BRCA testing (germline and somatic) was performed in 80 patients. BRCA1/BRCA2 pathogenic or likely pathogenic variant was found in 25% (n=20) patients. Upfront cytoreductive surgery was done only in 28% (n=65). Interval cytoreductive surgery was done in 66%(n=155) patients. Median overall survival for the entire study cohort was 45 months (95% CI, 32 to 47.5). Median overall survival for stage I, II, III, and IV was 62, 53, 38 and 23 months, respectively.
Conclusions
Most of the patients presented in advanced stage of the disease and have poor outcome. Lack of awareness delayed presentation and late diagnosis are resulting in poor outcomes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
153P - IMbrave150: Exploratory analyses for investigating associations between overall survival (OS) and depth of response (DpR) or duration of response (DoR) in patients (pts) with unresectable hepatocellular carcinoma (HCC)
Presenter: Masatoshi Kudo
Session: Poster Display
Resources:
Abstract
154P - Adverse events (AEs) as potential predictive factors of activity in patients with advanced hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (AB)
Presenter: Mara Persano
Session: Poster Display
Resources:
Abstract
155P - Penpulimab combined with anlotinib and nab-paclitaxel plus gemcitabine (PAAG) as first-line treatment for advanced metastatic pancreatic cancer: A prospective, multicenter, single-arm, phase II study
Presenter: Juan Du
Session: Poster Display
Resources:
Abstract
156P - Phase II trial of second-line regorafenib in patients with unresectable hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab: REGONEXT trial
Presenter: Jaekyung Cheon
Session: Poster Display
Resources:
Abstract
157P - T/N ratio and radiation dose delivered do not correlate with the development of Radioembolization-Induced Liver Disease (REILD) in Hepatocellular Carcinoma (HCC) following Y90 selective internal radiation therapy (Y90-SIRT): A retrospective, single tertiary centre cohort study
Presenter: Daniel Yang Yao Peh
Session: Poster Display
Resources:
Abstract
158P - Single-cell RNA sequencing via Endoscopic Ultrasoundguided Fine-Needle Biopsy (EUS-FNB) Pancreatic Biopsies uncovered an aggressive subclone with a poor prognosis
Presenter: Yung-yeh Su
Session: Poster Display
Resources:
Abstract
159P - Classical computer vision and modern deep-learning of pancreatic stroma histology features to diagnose cancer
Presenter: Abdelhakim Khellaf
Session: Poster Display
Resources:
Abstract
160P - Interim analysis of the NAPOLEON-2 study: Safety evaluation of nano-liposomal irinotecan with fluorouracil and folinic acid for advanced pancreatic cancer
Presenter: Wataru Kusano
Session: Poster Display
Resources:
Abstract
161P - Screening and COnsensus based on Practices and Evidence (SCOPE): Real-world survey on Japanese and rest-of-world practice patterns in resectable pancreatic cancer
Presenter: Elizabeth Smyth
Session: Poster Display
Resources:
Abstract
162P - Recurrence pattern of hepatocellular carcinoma patients receiving curative surgery of RFA: An update
Presenter: Long Chan
Session: Poster Display
Resources:
Abstract